Lactate dehydrogenase 5 expression in melanoma increases with disease progression and is associated with expression of Bcl-XL and Mcl-1, but ... View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2009-10-16

AUTHORS

Liqing Zhuang, Richard A Scolyer, Rajmohan Murali, Stanley W McCarthy, Xu Dong Zhang, John F Thompson, Peter Hersey

ABSTRACT

The serum level of lactate dehydrogenase (LDH) is an important predictor of prognosis and treatment response in melanoma patients. It is unknown whether the expression of LDH-5 in tissue sections also has prognostic significance and whether it is related to the expression of the anti-apoptotic proteins, Bcl-2, Bcl-XL and Mcl-1, and endoplasmic reticulum stress protein glucose-regulated protein 78 (GRP78). Identification of an association between LDH-5 expression and anti-apoptotic proteins may have important therapeutic implications for melanoma patients. Sections from 159 pigmented lesions, including nevi and melanoma at different stages of progression were studied by immunohistochemistry. Correlation of LDH-5 expression with clinicopathological factors and with the expression of Bcl-2, Bcl-XL, Mcl-1 and GRP78 was examined. LDH-5 was detected at low levels in 6 of 10 compound nevi (60%) and 6 of 10 dysplastic nevi (60%). The percentage of positive cases was greater in thin (≤1.0 mm) (74%) and thick primary melanoma (>1.0 mm) (95%) and in metastatic melanoma in the skin (100%) and lymph node (81%). The immunoreactive score was highly related to progression of melanoma (P<0.0001). LDH-5 expression was positively associated with increasing tumor thickness (P=0.02) and dermal tumor mitotic rate (P=0.02). LDH-5 above the median immunoreactive score was associated with reduced disease-free survival and overall survival (P<0.02). LDH-5 expression was negatively associated with Bcl-2 expression. In contrast, LDH-5 expression was strongly associated with Bcl-XL and Mcl-1 expression and also positively associated with GRP78 expression (P<0.0001). The low Bcl-2 expression in melanomas with high LDH-5 expression provides an explanation for the poor response of patients with high serum LDH levels to treatment with the Bcl-2 antisense drug ‘Genasense’. The strong correlation of LDH-5 expression with Mcl-1 expression suggests that treatment strategies inhibiting the activity of Mcl-1 in melanoma patients should be investigated. More... »

PAGES

45-53

Identifiers

URI

http://scigraph.springernature.com/pub.10.1038/modpathol.2009.129

DOI

http://dx.doi.org/10.1038/modpathol.2009.129

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1053552098

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/19838163


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adolescent", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged, 80 and over", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Biomarkers, Tumor", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Disease Progression", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Disease-Free Survival", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Endoplasmic Reticulum Chaperone BiP", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Immunohistochemistry", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Isoenzymes", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Kaplan-Meier Estimate", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "L-Lactate Dehydrogenase", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Lactate Dehydrogenase 5", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Melanoma", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Myeloid Cell Leukemia Sequence 1 Protein", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Nevus", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Precancerous Conditions", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Prognosis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Proto-Oncogene Proteins c-bcl-2", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Skin Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Young Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "bcl-X Protein", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Melanoma Institute Australia and Sydney Melanoma Unit, Royal Prince Alfred and Mater Hospitals, Sydney, NSW, Australia", 
          "id": "http://www.grid.ac/institutes/grid.419690.3", 
          "name": [
            "Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, Sydney, NSW, Australia", 
            "Melanoma Institute Australia and Sydney Melanoma Unit, Royal Prince Alfred and Mater Hospitals, Sydney, NSW, Australia"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Zhuang", 
        "givenName": "Liqing", 
        "id": "sg:person.01317747505.62", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01317747505.62"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Discipline of Pathology, Sydney Medical School, The University of Sydney, Sydney, NSW, Australia", 
          "id": "http://www.grid.ac/institutes/grid.1013.3", 
          "name": [
            "Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, Sydney, NSW, Australia", 
            "Melanoma Institute Australia and Sydney Melanoma Unit, Royal Prince Alfred and Mater Hospitals, Sydney, NSW, Australia", 
            "Discipline of Pathology, Sydney Medical School, The University of Sydney, Sydney, NSW, Australia"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Scolyer", 
        "givenName": "Richard A", 
        "id": "sg:person.01276020470.05", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01276020470.05"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Discipline of Pathology, Sydney Medical School, The University of Sydney, Sydney, NSW, Australia", 
          "id": "http://www.grid.ac/institutes/grid.1013.3", 
          "name": [
            "Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, Sydney, NSW, Australia", 
            "Melanoma Institute Australia and Sydney Melanoma Unit, Royal Prince Alfred and Mater Hospitals, Sydney, NSW, Australia", 
            "Discipline of Pathology, Sydney Medical School, The University of Sydney, Sydney, NSW, Australia"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Murali", 
        "givenName": "Rajmohan", 
        "id": "sg:person.01333577301.55", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01333577301.55"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Discipline of Pathology, Sydney Medical School, The University of Sydney, Sydney, NSW, Australia", 
          "id": "http://www.grid.ac/institutes/grid.1013.3", 
          "name": [
            "Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, Sydney, NSW, Australia", 
            "Discipline of Pathology, Sydney Medical School, The University of Sydney, Sydney, NSW, Australia"
          ], 
          "type": "Organization"
        }, 
        "familyName": "McCarthy", 
        "givenName": "Stanley W", 
        "id": "sg:person.01261211340.53", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01261211340.53"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Oncology and Immunology Unit, Calvary Mater Newcastle, NSW, Australia", 
          "id": "http://www.grid.ac/institutes/grid.413265.7", 
          "name": [
            "Oncology and Immunology Unit, Calvary Mater Newcastle, NSW, Australia"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Zhang", 
        "givenName": "Xu Dong", 
        "id": "sg:person.01210116316.18", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01210116316.18"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Discipline of Surgery, Sydney Medical School, The University of Sydney, Sydney, NSW, Australia", 
          "id": "http://www.grid.ac/institutes/grid.1013.3", 
          "name": [
            "Melanoma Institute Australia and Sydney Melanoma Unit, Royal Prince Alfred and Mater Hospitals, Sydney, NSW, Australia", 
            "Discipline of Surgery, Sydney Medical School, The University of Sydney, Sydney, NSW, Australia"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Thompson", 
        "givenName": "John F", 
        "id": "sg:person.013721017504.77", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013721017504.77"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Oncology and Immunology Unit, Calvary Mater Newcastle, NSW, Australia", 
          "id": "http://www.grid.ac/institutes/grid.413265.7", 
          "name": [
            "Melanoma Institute Australia and Sydney Melanoma Unit, Royal Prince Alfred and Mater Hospitals, Sydney, NSW, Australia", 
            "Oncology and Immunology Unit, Calvary Mater Newcastle, NSW, Australia"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hersey", 
        "givenName": "Peter", 
        "id": "sg:person.01073667716.42", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01073667716.42"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/s10495-005-3088-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1045885620", 
          "https://doi.org/10.1007/s10495-005-3088-0"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/modpathol.3800750", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1022673157", 
          "https://doi.org/10.1038/modpathol.3800750"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1159/000074430", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1041627432", 
          "https://doi.org/10.1159/000074430"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2009-10-16", 
    "datePublishedReg": "2009-10-16", 
    "description": "The serum level of lactate dehydrogenase (LDH) is an important predictor of prognosis and treatment response in melanoma patients. It is unknown whether the expression of LDH-5 in tissue sections also has prognostic significance and whether it is related to the expression of the anti-apoptotic proteins, Bcl-2, Bcl-XL and Mcl-1, and endoplasmic reticulum stress protein glucose-regulated protein 78 (GRP78). Identification of an association between LDH-5 expression and anti-apoptotic proteins may have important therapeutic implications for melanoma patients. Sections from 159 pigmented lesions, including nevi and melanoma at different stages of progression were studied by immunohistochemistry. Correlation of LDH-5 expression with clinicopathological factors and with the expression of Bcl-2, Bcl-XL, Mcl-1 and GRP78 was examined. LDH-5 was detected at low levels in 6 of 10 compound nevi (60%) and 6 of 10 dysplastic nevi (60%). The percentage of positive cases was greater in thin (\u22641.0\u2009mm) (74%) and thick primary melanoma (>1.0\u2009mm) (95%) and in metastatic melanoma in the skin (100%) and lymph node (81%). The immunoreactive score was highly related to progression of melanoma (P<0.0001). LDH-5 expression was positively associated with increasing tumor thickness (P=0.02) and dermal tumor mitotic rate (P=0.02). LDH-5 above the median immunoreactive score was associated with reduced disease-free survival and overall survival (P<0.02). LDH-5 expression was negatively associated with Bcl-2 expression. In contrast, LDH-5 expression was strongly associated with Bcl-XL and Mcl-1 expression and also positively associated with GRP78 expression (P<0.0001). The low Bcl-2 expression in melanomas with high LDH-5 expression provides an explanation for the poor response of patients with high serum LDH levels to treatment with the Bcl-2 antisense drug \u2018Genasense\u2019. The strong correlation of LDH-5 expression with Mcl-1 expression suggests that treatment strategies inhibiting the activity of Mcl-1 in melanoma patients should be investigated.", 
    "genre": "article", 
    "id": "sg:pub.10.1038/modpathol.2009.129", 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1098208", 
        "issn": [
          "0893-3952", 
          "1530-0285"
        ], 
        "name": "Modern Pathology", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "23"
      }
    ], 
    "keywords": [
      "LDH-5 expression", 
      "melanoma patients", 
      "Bcl-2 expression", 
      "immunoreactive score", 
      "Mcl-1 expression", 
      "anti-apoptotic proteins", 
      "high LDH-5 expression", 
      "Lactate Dehydrogenase 5 Expression", 
      "high serum LDH levels", 
      "LDH-5", 
      "reduced disease-free survival", 
      "Mcl-1", 
      "disease-free survival", 
      "serum LDH levels", 
      "thick primary melanomas", 
      "low Bcl-2 expression", 
      "lactate dehydrogenase", 
      "Bcl-xL", 
      "Bcl-2", 
      "tumor mitotic rate", 
      "important therapeutic implications", 
      "glucose-regulated protein 78", 
      "progression of melanoma", 
      "median immunoreactive scores", 
      "overall survival", 
      "lymph nodes", 
      "serum levels", 
      "clinicopathological factors", 
      "prognostic significance", 
      "tumor thickness", 
      "LDH levels", 
      "metastatic melanoma", 
      "melanoma increases", 
      "primary melanoma", 
      "poor response", 
      "disease progression", 
      "treatment strategies", 
      "treatment response", 
      "therapeutic implications", 
      "compound nevi", 
      "positive cases", 
      "mitotic rate", 
      "patients", 
      "pigmented lesions", 
      "melanoma", 
      "dysplastic nevi", 
      "GRP78 expression", 
      "Bcl-2 protein", 
      "protein 78", 
      "nevi", 
      "tissue sections", 
      "progression", 
      "important predictor", 
      "survival", 
      "antisense drugs", 
      "scores", 
      "expression", 
      "low levels", 
      "prognosis", 
      "immunohistochemistry", 
      "lesions", 
      "levels", 
      "strong correlation", 
      "protein", 
      "response", 
      "drugs", 
      "GRP78", 
      "different stages", 
      "skin", 
      "treatment", 
      "predictors", 
      "association", 
      "Genasense", 
      "correlation", 
      "percentage", 
      "dehydrogenase", 
      "factors", 
      "significance", 
      "cases", 
      "activity", 
      "rate", 
      "increase", 
      "contrast", 
      "sections", 
      "stage", 
      "identification", 
      "strategies", 
      "nodes", 
      "implications", 
      "explanation", 
      "thickness"
    ], 
    "name": "Lactate dehydrogenase 5 expression in melanoma increases with disease progression and is associated with expression of Bcl-XL and Mcl-1, but not Bcl-2 proteins", 
    "pagination": "45-53", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1053552098"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1038/modpathol.2009.129"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "19838163"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1038/modpathol.2009.129", 
      "https://app.dimensions.ai/details/publication/pub.1053552098"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-11-24T20:54", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20221124/entities/gbq_results/article/article_480.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1038/modpathol.2009.129"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1038/modpathol.2009.129'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1038/modpathol.2009.129'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1038/modpathol.2009.129'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1038/modpathol.2009.129'


 

This table displays all metadata directly associated to this object as RDF triples.

322 TRIPLES      21 PREDICATES      145 URIs      134 LITERALS      33 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1038/modpathol.2009.129 schema:about N01ccabb6cd7946c7a32f4bb7dc9d5aa1
2 N0ed1ab39c3f743e491c49ecf2d3b0343
3 N11f98c7aad17410eb4ffdf612aeb78be
4 N19b945301520404ea12eff2b8abe05dc
5 N1a042c2fe91e4a07b374a4f5bd3340ff
6 N2f99736a1a4b4710ba21f9e1efeed096
7 N3942831e2aa74ab9a6af84abe58787be
8 N4edbdad64da546cd8aa93fe6e45aa025
9 N4fc009b3a7364b5097bb6a70ea19c3a4
10 N5389d0e8c6d246c8969a78655df8cb11
11 N556e33bc2bb54bdca4f8f088b101caad
12 N5bf5c47e81cb4217a6a4bf6400470416
13 N5eada6eca4e04e7fa38b66ba4b1ffd01
14 N67d5353190c04674a49398c29cd76aba
15 N76b62e6a9eb742df8c07af89a4b0e05f
16 N9138b17f1b824a39b279846e091837a2
17 N95e5efb784274e1bb2a1aa02ef47b557
18 N9aff814d649b405bade08c0c1465d4b2
19 Na0424b1bb1a246c29c203ee2ee50668c
20 Na5442585409b441ea14962014f4704f8
21 Naadebf8bd2d041038c89289ec7885d0e
22 Nbdd97b9ae2fc4af78c5a08e7f277d72d
23 Nc089aeff15ac43b5a3d191c24ccd097d
24 Nc1418c9faa364c929e173ffc3aec973e
25 Nf2fa15593f894d7e820c0eddbd39e06a
26 Nf6952fbbb9a84b98a1bd65b4a2f59701
27 anzsrc-for:11
28 anzsrc-for:1112
29 schema:author N254538e66cf744189bba7f54625ad0f5
30 schema:citation sg:pub.10.1007/s10495-005-3088-0
31 sg:pub.10.1038/modpathol.3800750
32 sg:pub.10.1159/000074430
33 schema:datePublished 2009-10-16
34 schema:datePublishedReg 2009-10-16
35 schema:description The serum level of lactate dehydrogenase (LDH) is an important predictor of prognosis and treatment response in melanoma patients. It is unknown whether the expression of LDH-5 in tissue sections also has prognostic significance and whether it is related to the expression of the anti-apoptotic proteins, Bcl-2, Bcl-XL and Mcl-1, and endoplasmic reticulum stress protein glucose-regulated protein 78 (GRP78). Identification of an association between LDH-5 expression and anti-apoptotic proteins may have important therapeutic implications for melanoma patients. Sections from 159 pigmented lesions, including nevi and melanoma at different stages of progression were studied by immunohistochemistry. Correlation of LDH-5 expression with clinicopathological factors and with the expression of Bcl-2, Bcl-XL, Mcl-1 and GRP78 was examined. LDH-5 was detected at low levels in 6 of 10 compound nevi (60%) and 6 of 10 dysplastic nevi (60%). The percentage of positive cases was greater in thin (≤1.0 mm) (74%) and thick primary melanoma (>1.0 mm) (95%) and in metastatic melanoma in the skin (100%) and lymph node (81%). The immunoreactive score was highly related to progression of melanoma (P<0.0001). LDH-5 expression was positively associated with increasing tumor thickness (P=0.02) and dermal tumor mitotic rate (P=0.02). LDH-5 above the median immunoreactive score was associated with reduced disease-free survival and overall survival (P<0.02). LDH-5 expression was negatively associated with Bcl-2 expression. In contrast, LDH-5 expression was strongly associated with Bcl-XL and Mcl-1 expression and also positively associated with GRP78 expression (P<0.0001). The low Bcl-2 expression in melanomas with high LDH-5 expression provides an explanation for the poor response of patients with high serum LDH levels to treatment with the Bcl-2 antisense drug ‘Genasense’. The strong correlation of LDH-5 expression with Mcl-1 expression suggests that treatment strategies inhibiting the activity of Mcl-1 in melanoma patients should be investigated.
36 schema:genre article
37 schema:isAccessibleForFree true
38 schema:isPartOf N5e965f63e17246a79663606ef6f9a86a
39 Nf51f94bd9e724238a123f06dbc6702a5
40 sg:journal.1098208
41 schema:keywords Bcl-2
42 Bcl-2 expression
43 Bcl-2 protein
44 Bcl-xL
45 GRP78
46 GRP78 expression
47 Genasense
48 LDH levels
49 LDH-5
50 LDH-5 expression
51 Lactate Dehydrogenase 5 Expression
52 Mcl-1
53 Mcl-1 expression
54 activity
55 anti-apoptotic proteins
56 antisense drugs
57 association
58 cases
59 clinicopathological factors
60 compound nevi
61 contrast
62 correlation
63 dehydrogenase
64 different stages
65 disease progression
66 disease-free survival
67 drugs
68 dysplastic nevi
69 explanation
70 expression
71 factors
72 glucose-regulated protein 78
73 high LDH-5 expression
74 high serum LDH levels
75 identification
76 immunohistochemistry
77 immunoreactive score
78 implications
79 important predictor
80 important therapeutic implications
81 increase
82 lactate dehydrogenase
83 lesions
84 levels
85 low Bcl-2 expression
86 low levels
87 lymph nodes
88 median immunoreactive scores
89 melanoma
90 melanoma increases
91 melanoma patients
92 metastatic melanoma
93 mitotic rate
94 nevi
95 nodes
96 overall survival
97 patients
98 percentage
99 pigmented lesions
100 poor response
101 positive cases
102 predictors
103 primary melanoma
104 prognosis
105 prognostic significance
106 progression
107 progression of melanoma
108 protein
109 protein 78
110 rate
111 reduced disease-free survival
112 response
113 scores
114 sections
115 serum LDH levels
116 serum levels
117 significance
118 skin
119 stage
120 strategies
121 strong correlation
122 survival
123 therapeutic implications
124 thick primary melanomas
125 thickness
126 tissue sections
127 treatment
128 treatment response
129 treatment strategies
130 tumor mitotic rate
131 tumor thickness
132 schema:name Lactate dehydrogenase 5 expression in melanoma increases with disease progression and is associated with expression of Bcl-XL and Mcl-1, but not Bcl-2 proteins
133 schema:pagination 45-53
134 schema:productId N415a3687f6834d5c8700088058f9e9db
135 Nd595049b076040d3b4e5d2dd0b90a821
136 Nf7267a6506114542a4dc85b3b12ba0e4
137 schema:sameAs https://app.dimensions.ai/details/publication/pub.1053552098
138 https://doi.org/10.1038/modpathol.2009.129
139 schema:sdDatePublished 2022-11-24T20:54
140 schema:sdLicense https://scigraph.springernature.com/explorer/license/
141 schema:sdPublisher N62d408fa8a3a4868ad37ee80798e4ced
142 schema:url https://doi.org/10.1038/modpathol.2009.129
143 sgo:license sg:explorer/license/
144 sgo:sdDataset articles
145 rdf:type schema:ScholarlyArticle
146 N01ccabb6cd7946c7a32f4bb7dc9d5aa1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
147 schema:name Immunohistochemistry
148 rdf:type schema:DefinedTerm
149 N0ed1ab39c3f743e491c49ecf2d3b0343 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
150 schema:name Prognosis
151 rdf:type schema:DefinedTerm
152 N11f98c7aad17410eb4ffdf612aeb78be schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
153 schema:name L-Lactate Dehydrogenase
154 rdf:type schema:DefinedTerm
155 N19b945301520404ea12eff2b8abe05dc schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
156 schema:name Disease Progression
157 rdf:type schema:DefinedTerm
158 N1a042c2fe91e4a07b374a4f5bd3340ff schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
159 schema:name Male
160 rdf:type schema:DefinedTerm
161 N254538e66cf744189bba7f54625ad0f5 rdf:first sg:person.01317747505.62
162 rdf:rest Necf9c8884c1a45b4a04228ab34c068bd
163 N2f99736a1a4b4710ba21f9e1efeed096 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
164 schema:name Aged, 80 and over
165 rdf:type schema:DefinedTerm
166 N38c1ac93b9224e12896307caef47911f rdf:first sg:person.01333577301.55
167 rdf:rest Na131359e5e8a43d59a52d10988ef1b4a
168 N3942831e2aa74ab9a6af84abe58787be schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
169 schema:name bcl-X Protein
170 rdf:type schema:DefinedTerm
171 N415a3687f6834d5c8700088058f9e9db schema:name doi
172 schema:value 10.1038/modpathol.2009.129
173 rdf:type schema:PropertyValue
174 N4edbdad64da546cd8aa93fe6e45aa025 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
175 schema:name Isoenzymes
176 rdf:type schema:DefinedTerm
177 N4fc009b3a7364b5097bb6a70ea19c3a4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
178 schema:name Skin Neoplasms
179 rdf:type schema:DefinedTerm
180 N5389d0e8c6d246c8969a78655df8cb11 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
181 schema:name Precancerous Conditions
182 rdf:type schema:DefinedTerm
183 N556e33bc2bb54bdca4f8f088b101caad schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
184 schema:name Biomarkers, Tumor
185 rdf:type schema:DefinedTerm
186 N5bf5c47e81cb4217a6a4bf6400470416 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
187 schema:name Nevus
188 rdf:type schema:DefinedTerm
189 N5e965f63e17246a79663606ef6f9a86a schema:volumeNumber 23
190 rdf:type schema:PublicationVolume
191 N5eada6eca4e04e7fa38b66ba4b1ffd01 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
192 schema:name Endoplasmic Reticulum Chaperone BiP
193 rdf:type schema:DefinedTerm
194 N62d408fa8a3a4868ad37ee80798e4ced schema:name Springer Nature - SN SciGraph project
195 rdf:type schema:Organization
196 N67d5353190c04674a49398c29cd76aba schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
197 schema:name Adult
198 rdf:type schema:DefinedTerm
199 N6b0f648f0d93450f82de9086167e376e rdf:first sg:person.01073667716.42
200 rdf:rest rdf:nil
201 N76b62e6a9eb742df8c07af89a4b0e05f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
202 schema:name Humans
203 rdf:type schema:DefinedTerm
204 N7afd49d7f1bc483383bd063fd18e360f rdf:first sg:person.013721017504.77
205 rdf:rest N6b0f648f0d93450f82de9086167e376e
206 N83c55f20dda445e1b6ef00ff5306eff3 rdf:first sg:person.01210116316.18
207 rdf:rest N7afd49d7f1bc483383bd063fd18e360f
208 N9138b17f1b824a39b279846e091837a2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
209 schema:name Female
210 rdf:type schema:DefinedTerm
211 N95e5efb784274e1bb2a1aa02ef47b557 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
212 schema:name Kaplan-Meier Estimate
213 rdf:type schema:DefinedTerm
214 N9aff814d649b405bade08c0c1465d4b2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
215 schema:name Proto-Oncogene Proteins c-bcl-2
216 rdf:type schema:DefinedTerm
217 Na0424b1bb1a246c29c203ee2ee50668c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
218 schema:name Myeloid Cell Leukemia Sequence 1 Protein
219 rdf:type schema:DefinedTerm
220 Na131359e5e8a43d59a52d10988ef1b4a rdf:first sg:person.01261211340.53
221 rdf:rest N83c55f20dda445e1b6ef00ff5306eff3
222 Na5442585409b441ea14962014f4704f8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
223 schema:name Melanoma
224 rdf:type schema:DefinedTerm
225 Naadebf8bd2d041038c89289ec7885d0e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
226 schema:name Middle Aged
227 rdf:type schema:DefinedTerm
228 Nbdd97b9ae2fc4af78c5a08e7f277d72d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
229 schema:name Disease-Free Survival
230 rdf:type schema:DefinedTerm
231 Nc089aeff15ac43b5a3d191c24ccd097d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
232 schema:name Aged
233 rdf:type schema:DefinedTerm
234 Nc1418c9faa364c929e173ffc3aec973e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
235 schema:name Adolescent
236 rdf:type schema:DefinedTerm
237 Nd595049b076040d3b4e5d2dd0b90a821 schema:name dimensions_id
238 schema:value pub.1053552098
239 rdf:type schema:PropertyValue
240 Necf9c8884c1a45b4a04228ab34c068bd rdf:first sg:person.01276020470.05
241 rdf:rest N38c1ac93b9224e12896307caef47911f
242 Nf2fa15593f894d7e820c0eddbd39e06a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
243 schema:name Young Adult
244 rdf:type schema:DefinedTerm
245 Nf51f94bd9e724238a123f06dbc6702a5 schema:issueNumber 1
246 rdf:type schema:PublicationIssue
247 Nf6952fbbb9a84b98a1bd65b4a2f59701 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
248 schema:name Lactate Dehydrogenase 5
249 rdf:type schema:DefinedTerm
250 Nf7267a6506114542a4dc85b3b12ba0e4 schema:name pubmed_id
251 schema:value 19838163
252 rdf:type schema:PropertyValue
253 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
254 schema:name Medical and Health Sciences
255 rdf:type schema:DefinedTerm
256 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
257 schema:name Oncology and Carcinogenesis
258 rdf:type schema:DefinedTerm
259 sg:journal.1098208 schema:issn 0893-3952
260 1530-0285
261 schema:name Modern Pathology
262 schema:publisher Springer Nature
263 rdf:type schema:Periodical
264 sg:person.01073667716.42 schema:affiliation grid-institutes:grid.413265.7
265 schema:familyName Hersey
266 schema:givenName Peter
267 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01073667716.42
268 rdf:type schema:Person
269 sg:person.01210116316.18 schema:affiliation grid-institutes:grid.413265.7
270 schema:familyName Zhang
271 schema:givenName Xu Dong
272 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01210116316.18
273 rdf:type schema:Person
274 sg:person.01261211340.53 schema:affiliation grid-institutes:grid.1013.3
275 schema:familyName McCarthy
276 schema:givenName Stanley W
277 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01261211340.53
278 rdf:type schema:Person
279 sg:person.01276020470.05 schema:affiliation grid-institutes:grid.1013.3
280 schema:familyName Scolyer
281 schema:givenName Richard A
282 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01276020470.05
283 rdf:type schema:Person
284 sg:person.01317747505.62 schema:affiliation grid-institutes:grid.419690.3
285 schema:familyName Zhuang
286 schema:givenName Liqing
287 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01317747505.62
288 rdf:type schema:Person
289 sg:person.01333577301.55 schema:affiliation grid-institutes:grid.1013.3
290 schema:familyName Murali
291 schema:givenName Rajmohan
292 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01333577301.55
293 rdf:type schema:Person
294 sg:person.013721017504.77 schema:affiliation grid-institutes:grid.1013.3
295 schema:familyName Thompson
296 schema:givenName John F
297 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013721017504.77
298 rdf:type schema:Person
299 sg:pub.10.1007/s10495-005-3088-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1045885620
300 https://doi.org/10.1007/s10495-005-3088-0
301 rdf:type schema:CreativeWork
302 sg:pub.10.1038/modpathol.3800750 schema:sameAs https://app.dimensions.ai/details/publication/pub.1022673157
303 https://doi.org/10.1038/modpathol.3800750
304 rdf:type schema:CreativeWork
305 sg:pub.10.1159/000074430 schema:sameAs https://app.dimensions.ai/details/publication/pub.1041627432
306 https://doi.org/10.1159/000074430
307 rdf:type schema:CreativeWork
308 grid-institutes:grid.1013.3 schema:alternateName Discipline of Pathology, Sydney Medical School, The University of Sydney, Sydney, NSW, Australia
309 Discipline of Surgery, Sydney Medical School, The University of Sydney, Sydney, NSW, Australia
310 schema:name Discipline of Pathology, Sydney Medical School, The University of Sydney, Sydney, NSW, Australia
311 Discipline of Surgery, Sydney Medical School, The University of Sydney, Sydney, NSW, Australia
312 Melanoma Institute Australia and Sydney Melanoma Unit, Royal Prince Alfred and Mater Hospitals, Sydney, NSW, Australia
313 Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, Sydney, NSW, Australia
314 rdf:type schema:Organization
315 grid-institutes:grid.413265.7 schema:alternateName Oncology and Immunology Unit, Calvary Mater Newcastle, NSW, Australia
316 schema:name Melanoma Institute Australia and Sydney Melanoma Unit, Royal Prince Alfred and Mater Hospitals, Sydney, NSW, Australia
317 Oncology and Immunology Unit, Calvary Mater Newcastle, NSW, Australia
318 rdf:type schema:Organization
319 grid-institutes:grid.419690.3 schema:alternateName Melanoma Institute Australia and Sydney Melanoma Unit, Royal Prince Alfred and Mater Hospitals, Sydney, NSW, Australia
320 schema:name Melanoma Institute Australia and Sydney Melanoma Unit, Royal Prince Alfred and Mater Hospitals, Sydney, NSW, Australia
321 Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, Sydney, NSW, Australia
322 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...